Blood Res (2024) 59:13
Published online March 25, 2024
https://doi.org/10.1007/s44313-024-00013-x
© The Korean Society of Hematology
Correspondence to : *Jinlin Liu
liujinlinhz@163.com
†Can Yan and Zenghui Fang contributed equally to this work.
Keywords: Pseudo-chediak-higashi inclusions, Disseminated diffuse large B cell lymphoma
A 45-year-old male was admitted to the hospital with complaints of malaise, chest tightness, and abdominal distension persisting for two weeks. Physical examination revealed pleural and peritoneal effusions. Initial hematological results showed a hemoglobin level of 74 g/L and a platelet count of 45 × 109/L. A blood smear showed peripheral blood involvement (10%) through lymphoma-like cells, and bone marrow aspiration showed involvement of these lymphoma-like cells (90%) (Fig. 1A). These cells exhibited nuclear indentation and eccentric nuclei. Notably, a few giant pink-purple inclusions (chédiak-higashi-like inclusions) were observed in the cytoplasm of these lymphoma-like cells (Fig. 1A). These inclusions were situated adjacent to the nucleus and displayed variations in size, with negative myeloperoxidase staining (Fig. 1B) and positive Schiff periodic acid-shift staining (Fig. 1C). Furthermore, cytological examination of pleural and peritoneal fluid revealed infiltration by the same cells harboring pseudo-chediak higashi inclusions. Flow cytometry analysis demonstrated positivity for FMC7, CD10, CD19, CD20, CD22, kappa, HLA-DR, and CD200. Cytogenetic studies showed 46, xy, dup (12) (q13 q21), t(14:18), (q32; q21.3) [4] /46, xy [10]. Genetic testing revealed KMT2D p.Q1029*, KMT2D p.P4865Lfs*5, and EZH2 p.Y646S using the Illumina next-generation sequencing platform. Consequently, a diagnosis of disseminated EZB type diffuse large B-cell lymphoma (EZB-DLBCL) was established. After the diagnosis of disseminated DLBCL, the patient underwent four cycles of R-CHOP and received intrathecal injections (cytarabine, methotrexate, and dexamethasone) once. The tumor burden significantly decreased, as evidenced by PET-CT, and stem cell transplantation was considered before manuscript submission.
Pseudo-Chediak-Higashi inclusions are occasionally reported in various hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and mixed-phenotype acute leukemia, referred to as pseudo-Chédiak-Higashi anomalies, with unclear pathogenesis [1, 2]. These inclusions are typically not observed in patients with lymphoma, making the presence of rare pseudo-Chediak-Higashi inclusion in a disseminated EZB-DLBCL patient exceptional.
No thanks
Can Yan and Zenghui Fang provide the clinical case and guided the clinical diagnosis. Jinlin Liu designed the study and wrote the manuscript.
None.
No datasets were generated or analysed during the current study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ethics approval and consent to participate
This study was approved by the ethics committees of the Jinhua Municipal Central Hospital and Jinhua Hospital of Zhejiang University, Jinhua, China.
Competing interests
The authors declare no competing interests.
Blood Res 2024; 59():
Published online March 25, 2024 https://doi.org/10.1007/s44313-024-00013-x
Copyright © The Korean Society of Hematology.
Can Yan1†, Zenghui Fang1† and Jinlin Liu2*
1Department of Clinical Laboratory, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University, Jinhua, China
2Department of Clinical Laboratory, South China Hospital, Medical School, Shenzhen University, 1 Fuxin Road, Shenzhen 518111, China
Correspondence to:*Jinlin Liu
liujinlinhz@163.com
†Can Yan and Zenghui Fang contributed equally to this work.
A 45-year-old male was admitted to the hospital with complaints of malaise, chest tightness, and abdominal distension persisting for two weeks. Physical examination revealed pleural and peritoneal effusions. Initial hematological results showed a hemoglobin level of 74 g/L and a platelet count of 45 × 109/L. A blood smear showed peripheral blood involvement (10%) through lymphoma-like cells, and bone marrow aspiration showed involvement of these lymphoma-like cells (90%) (Fig. 1A). These cells exhibited nuclear indentation and eccentric nuclei. Notably, a few giant pink-purple inclusions (chédiak-higashi-like inclusions) were observed in the cytoplasm of these lymphoma-like cells (Fig. 1A). These inclusions were situated adjacent to the nucleus and displayed variations in size, with negative myeloperoxidase staining (Fig. 1B) and positive Schiff periodic acid-shift staining (Fig. 1C). Furthermore, cytological examination of pleural and peritoneal fluid revealed infiltration by the same cells harboring pseudo-chediak higashi inclusions. Flow cytometry analysis demonstrated positivity for FMC7, CD10, CD19, CD20, CD22, kappa, HLA-DR, and CD200. Cytogenetic studies showed 46, xy, dup (12) (q13 q21), t(14:18), (q32; q21.3) [4] /46, xy [10]. Genetic testing revealed KMT2D p.Q1029*, KMT2D p.P4865Lfs*5, and EZH2 p.Y646S using the Illumina next-generation sequencing platform. Consequently, a diagnosis of disseminated EZB type diffuse large B-cell lymphoma (EZB-DLBCL) was established. After the diagnosis of disseminated DLBCL, the patient underwent four cycles of R-CHOP and received intrathecal injections (cytarabine, methotrexate, and dexamethasone) once. The tumor burden significantly decreased, as evidenced by PET-CT, and stem cell transplantation was considered before manuscript submission.
Pseudo-Chediak-Higashi inclusions are occasionally reported in various hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and mixed-phenotype acute leukemia, referred to as pseudo-Chédiak-Higashi anomalies, with unclear pathogenesis [1, 2]. These inclusions are typically not observed in patients with lymphoma, making the presence of rare pseudo-Chediak-Higashi inclusion in a disseminated EZB-DLBCL patient exceptional.
No thanks
Can Yan and Zenghui Fang provide the clinical case and guided the clinical diagnosis. Jinlin Liu designed the study and wrote the manuscript.
None.
No datasets were generated or analysed during the current study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ethics approval and consent to participate
This study was approved by the ethics committees of the Jinhua Municipal Central Hospital and Jinhua Hospital of Zhejiang University, Jinhua, China.
Competing interests
The authors declare no competing interests.